BioCentury | Apr 30, 2020
Deals

Adicet to become public company via resTORbio merger

...Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade...
...for a contingent value right payable to resTORbio’s shareholders under certain conditions. In November 2019, resTORbio...
...equity, and resTORbio’s will hold the balance. The combined company's president and CEO will be resTORbio...
BioCentury | Nov 15, 2019
Clinical News

resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

...company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications. resTORbio Inc....
...IIb trial in July 2018, non-significantly reducing CSRIs by 15.3% vs. placebo (one-sided p=0.27). But resTORbio...
...“resTORbio Forging Ahead With Anti-infective After Phase IIb Readout” ). On a conference call Friday, resTORbio...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc. (NASDAQ:DERM) 3/21/19 $149.5 $710.3 $513.1 -28% resTORbio Inc....
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...could treat the disease. By contrast, Dionne said other companies with autophagy-related programs, including resTORbio Inc....
...of preparation and filing but did not disclose what the IP covers. A spokesperson for resTORbio...
...Therapeutics Inc., Cambridge, Mass. Michael J. Fox Foundation For Parkinson's Research (MJFF), New York, N.Y. resTORbio Inc....
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

...NASDAQ:DTIL) hired Christopher Heery as CMO. He was CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY). resTORbio Inc....
...Corp. Amunix Pharmaceuticals Inc. Beam Therapeutics CytoDyn Inc. DBV Technologies S.A. Glympse Bio Inc. Life Biosciences LLC Novigenix S.A. Precision BioSciences Inc. Rafael Pharmaceuticals Inc. resTORbio Inc....
BioCentury | Mar 20, 2019
Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

...million in an upsized offering that followed closely after its eczema readout this week, while resTORbio...
...Fitzgerald, Guggenheim Securities, Needham and H.C. Wainwright. Dermira was off $0.49 to $13.64 on Wednesday. resTORbio Inc....
...pricing 7.2 million shares at $6.95, a 23% discount to Monday's closing price of $9.05. resTORbio...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...with seven pharmas. PureTech holds a majority stake in eight of its 10 private companies. resTORbio Inc....
...and Merck KGaA (Xetra:MRK) are investors rather than collaborators in Akili Interactive Labs Inc. (B) resTORbio...
...58.4% Phase II None Sonde Health Voice-based biomarkers Neurology 93.1% Phase I None IMMUNE SYSTEM resTORbio Inc....
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...chief commercial officer. He was SVP of commercial at Heron Therapeutics Inc. (NASDAQ:HRTX). Aging company resTORbio Inc....
...Therapeutics Inc. BioTime Inc. Deciphera Pharmaceuticals Inc. Flatiron Health Inc. Gamida Cell Ltd. Genentech Inc. Heron Therapeutics Inc. Immune-Onc Therapeutics Inc. Melinta Therapeutics Inc. resTORbio Inc. Roche Shire...
BioCentury | Aug 30, 2018
Financial News

PureTech Founder Steinberg departs for Longwood Fund

...Fund, but did not specify his new role. Steinberg has co-founded several biotechs, including PureTech, resTORbio Inc....
BioCentury | Jul 27, 2018
Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

...Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent...
...trial's Parts 1 and 2 in which one dose did significantly improve the primary endpoint, resTORbio...
...ages 65 and older with asthma, and patients ages 65 and older who are non-smokers. resTORbio...
Items per page:
1 - 10 of 26
BioCentury | Apr 30, 2020
Deals

Adicet to become public company via resTORbio merger

...Cell therapy developer Adicet will merge with resTORbio to form a public company that will trade...
...for a contingent value right payable to resTORbio’s shareholders under certain conditions. In November 2019, resTORbio...
...equity, and resTORbio’s will hold the balance. The combined company's president and CEO will be resTORbio...
BioCentury | Nov 15, 2019
Clinical News

resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

...company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications. resTORbio Inc....
...IIb trial in July 2018, non-significantly reducing CSRIs by 15.3% vs. placebo (one-sided p=0.27). But resTORbio...
...“resTORbio Forging Ahead With Anti-infective After Phase IIb Readout” ). On a conference call Friday, resTORbio...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NYSE-M:OGEN) (A) 3/22/19 $12.5 NA $22.6 NA Dermira Inc. (NASDAQ:DERM) 3/21/19 $149.5 $710.3 $513.1 -28% resTORbio Inc....
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...could treat the disease. By contrast, Dionne said other companies with autophagy-related programs, including resTORbio Inc....
...of preparation and filing but did not disclose what the IP covers. A spokesperson for resTORbio...
...Therapeutics Inc., Cambridge, Mass. Michael J. Fox Foundation For Parkinson's Research (MJFF), New York, N.Y. resTORbio Inc....
BioCentury | May 14, 2019
Company News

Management tracks: DBV, Beam, Aeon Biopharma

...NASDAQ:DTIL) hired Christopher Heery as CMO. He was CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY). resTORbio Inc....
...Corp. Amunix Pharmaceuticals Inc. Beam Therapeutics CytoDyn Inc. DBV Technologies S.A. Glympse Bio Inc. Life Biosciences LLC Novigenix S.A. Precision BioSciences Inc. Rafael Pharmaceuticals Inc. resTORbio Inc....
BioCentury | Mar 20, 2019
Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

...million in an upsized offering that followed closely after its eczema readout this week, while resTORbio...
...Fitzgerald, Guggenheim Securities, Needham and H.C. Wainwright. Dermira was off $0.49 to $13.64 on Wednesday. resTORbio Inc....
...pricing 7.2 million shares at $6.95, a 23% discount to Monday's closing price of $9.05. resTORbio...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...with seven pharmas. PureTech holds a majority stake in eight of its 10 private companies. resTORbio Inc....
...and Merck KGaA (Xetra:MRK) are investors rather than collaborators in Akili Interactive Labs Inc. (B) resTORbio...
...58.4% Phase II None Sonde Health Voice-based biomarkers Neurology 93.1% Phase I None IMMUNE SYSTEM resTORbio Inc....
BioCentury | Sep 18, 2018
Company News

Management tracks: BioTime, Immune-Onc

...chief commercial officer. He was SVP of commercial at Heron Therapeutics Inc. (NASDAQ:HRTX). Aging company resTORbio Inc....
...Therapeutics Inc. BioTime Inc. Deciphera Pharmaceuticals Inc. Flatiron Health Inc. Gamida Cell Ltd. Genentech Inc. Heron Therapeutics Inc. Immune-Onc Therapeutics Inc. Melinta Therapeutics Inc. resTORbio Inc. Roche Shire...
BioCentury | Aug 30, 2018
Financial News

PureTech Founder Steinberg departs for Longwood Fund

...Fund, but did not specify his new role. Steinberg has co-founded several biotechs, including PureTech, resTORbio Inc....
BioCentury | Jul 27, 2018
Clinical News

resTORbio forging ahead with anti-infective after Phase IIb readout

...Data from Part 2 of a Phase IIb trial evaluating RTB101 from resTORbio Inc. (NASDAQ:TORC) to prevent...
...trial's Parts 1 and 2 in which one dose did significantly improve the primary endpoint, resTORbio...
...ages 65 and older with asthma, and patients ages 65 and older who are non-smokers. resTORbio...
Items per page:
1 - 10 of 26